Lilly drug wins U.K. backing as cancer therapy

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for patients with the most common form of lung cancer.

Alimta, or pemetrexed, would be the first drug to be made available for this type of therapy in the U.K. if the draft guidance issued Wednesday becomes final, the National Institute for Health and Clinical Excellence said in an e-mailed statement. The agency, known as NICE, evaluates the cost-effectiveness of care for the state-run National Health Service.

The medicine is already recommended by NICE as an initial treatment for non-small cell lung cancer, which accounts for about 80 percent of all lung cancer cases. The main goals of maintenance treatment are to prolong remission after initial chemotherapy and increase the likelihood of receiving second-line chemotherapy, according to NICE.

“It is a new concept in lung cancer care,” Peter Littlejohns, the clinical and public health director at NICE, said in the statement.

Alimta, which can potentially extend patients’ lives by about 5.2 months, costs roughly $18,000 a year, according to NICE. Sales of the medicine rose 64 percent in the fourth quarter, to $523.6 million, Indianapolis-based Lilly said.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ